Clinical Context
A typical patient is a postmenopausal woman or an adult with osteoporosis or bone loss who presents to an outpatient infusion or injection clinic for administration of denosumab biosimilar. The medication Q5162 (injection, denosumab-nxxp, biosimilar, 1 mg) is supplied as a prefilled syringe or vial for subcutaneous injection. Clinical workflow includes verification of indication and recent bone mineral density testing or fracture history, medication reconciliation (noting prior osteoporosis therapies and calcium/vitamin D supplementation), informed consent and counseling on potential adverse effects (hypocalcemia, infections, dermatologic reactions), baseline serum calcium measurement if not recently available, preparation of the product by nursing staff according to clinic protocol, subcutaneous administration (typically in the upper arm, abdomen, or thigh), and post-injection observation for immediate adverse reaction per facility policy. Billing staff capture the Q5162 HCPCS Level II code along with the appropriate payer information (for example, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare) and any applicable modifiers reflecting service specifics. Typical site of service is an outpatient infusion/injection clinic, physician office, or hospital outpatient department. Typical patient scenario: a 68-year-old woman with osteoporosis and a prior vertebral compression fracture receiving a routine six-month denosumab biosimilar injection during a scheduled clinic visit with prior labs reviewed and documentation of counseling and post-injection observation.
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Commonly billed for the administration service when a separate syringe or administration fee applies alongside the drug HCPCS code Q5162. |
36415 | Collection of venous blood by venipuncture | Performed for baseline or monitoring labs such as serum calcium prior to or after denosumab administration.
99070 | Supplies and materials (except spectacles), provided by the physician over and above those usually included with the office visit or procedure | Used to bill for additional supplies associated with injection administration when payer allows.
96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | Not typically used for subcutaneous denosumab but listed if infusion suite resources are billed for observation or infusion-related services.
99406 | Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes | Ancillary preventive counseling sometimes provided during the visit; not directly related but may be documented during the same encounter.